Association of Blood Concentrations of Complement Split Product iC3b and Serum C3 With Systemic Lupus Erythematosus Disease Activity

被引:40
作者
Kim, Alfred H. J. [1 ]
Strand, Vibeke [2 ]
Sen, Deepali P. [1 ]
Fu, Qiang [3 ]
Mathis, Nancy L. [1 ]
Schmidt, Martin J. [4 ]
Bruchas, Robin R. [4 ]
Staten, Nick R. [1 ,4 ]
Olson, Paul K. [4 ,5 ]
Stiening, Chad M. [4 ,6 ]
Atkinson, John P. [1 ]
机构
[1] Washington Univ, Sch Med, St Louis, MO 63110 USA
[2] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA
[3] St Louis Univ, St Louis, MO 63103 USA
[4] Pulse Therapeut Inc, St Louis, MO USA
[5] Common Pl Holdings, St Louis, MO USA
[6] Kypha Inc, St Louis, MO USA
关键词
ACTIVATION PRODUCTS; REACTIVE PROTEIN; PLASMA; COMPONENT; C4D; CLASSIFICATION; ANAPHYLATOXINS; EXACERBATIONS; EXPRESSION; BIOMARKERS;
D O I
10.1002/art.40747
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To examine correlations between blood levels of complement split product iC3b and serum component C3 with clinically meaningful changes in disease activity in patients with systemic lupus erythematosus (SLE). Methods A total of 159 consecutive patients with SLE, diagnosed according to the American College of Rheumatology or Systemic Lupus International Collaborating Clinics classification criteria, were enrolled in CASTLE (Complement Activation Signatures in Systemic Lupus Erythematosus), a prospective observational study. Patients with 1-7 study visits were included in this longitudinal analysis. In addition, 48 healthy volunteers were enrolled to establish a normal reference value for the ratio of blood iC3b to serum C3 concentrations. Serum C3 and C4 levels were measured by nephelometry, and blood iC3b levels were measured by a lateral flow assay. SLE disease activity was monitored with the Responder Index 50 instrument of the SLE Disease Activity Index 2000. Results Relative changes in the iC3b:C3 ratio, levels of anti-double-stranded DNA (anti-dsDNA) antibodies, and use of a supraphysiologic dose of prednisone (>7.5 mg/day) each independently correlated with SLE disease activity, as determined in multilevel multiple logistic regression analyses. Only the iC3b:C3 ratio was significantly associated with clinically meaningful improvements in disease activity among patients with SLE who were receiving a supraphysiologic dose of prednisone. The iC3b:C3 ratio outperformed C3 and C4 levels with regard to discriminating active SLE from inactive SLE, and major flares from no disease activity. The iC3:C3 ratio, anti-dsDNA antibody levels, erythrocyte sedimentation rate, and use of a supraphysiologic prednisone dose were each independently associated with the presence of lupus nephritis, whereas none of these measures was associated with SLE rash. The association of the iC3b:C3 ratio with lupus nephritis was independent of other observed clinical manifestations. Conclusion The ratio of blood iC3b to serum C3 concentrations correlates with the extent of SLE disease activity and with clinically meaningful changes in disease activity in patients with SLE. Furthermore, the iC3b:C3 ratio may discriminate between active and inactive SLE, and between major flares and no active disease.
引用
收藏
页码:420 / 430
页数:11
相关论文
共 59 条
[1]   COMPLEMENT ACTIVATION AND COMPLEMENT RECEPTORS IN SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
ATKINSON, JP .
SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 1986, 9 (2-3) :179-194
[2]   ISOLATION AND ANALYSIS OF COMPLEMENT ACTIVATING AGGREGATES FROM SYNOVIAL-FLUID OF PATIENTS WITH RHEUMATOID-ARTHRITIS USING MONOCLONAL ANTI-C3D ANTIBODIES [J].
BEDWELL, AE ;
ELSON, CJ ;
CARTER, SD ;
DIEPPE, PA ;
HUTTON, CW ;
CZUDEK, R .
ANNALS OF THE RHEUMATIC DISEASES, 1987, 46 (01) :55-64
[3]   COMPLEMENT ACTIVATION DURING SYSTEMIC LUPUS-ERYTHEMATOSUS - C3A AND C5A ANAPHYLATOXINS CIRCULATE DURING EXACERBATIONS OF DISEASE [J].
BELMONT, HM ;
HOPKINS, P ;
EDELSON, HS ;
KAPLAN, HB ;
LUDEWIG, R ;
WEISSMANN, G ;
ABRAMSON, S .
ARTHRITIS AND RHEUMATISM, 1986, 29 (09) :1085-1089
[4]   The complex nature of serum C3 and C4 as biomarkers of lupus renal flare [J].
Birmingham, D. J. ;
Irshaid, F. ;
Nagaraja, H. N. ;
Zou, X. ;
Tsao, B. P. ;
Wu, H. ;
Yu, C. Y. ;
Hebert, L. A. ;
Rovin, B. H. .
LUPUS, 2010, 19 (11) :1272-1280
[5]   Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus [J].
Buyon, Jill ;
Furie, Richard ;
Putterman, Chaim ;
Ramsey-Goldman, Rosalind ;
Kalunian, Kenneth ;
Barken, Derren ;
Conklin, John ;
Dervieux, Thierry .
LUPUS SCIENCE & MEDICINE, 2016, 3 (01)
[6]   ASSESSMENT OF DISEASE-ACTIVITY AND IMPENDING FLARE IN PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS - COMPARISON OF THE USE OF COMPLEMENT SPLIT PRODUCTS AND CONVENTIONAL MEASUREMENTS OF COMPLEMENT [J].
BUYON, JP ;
TAMERIUS, J ;
BELMONT, HM ;
ABRAMSON, SB .
ARTHRITIS AND RHEUMATISM, 1992, 35 (09) :1028-1037
[7]  
Calano SJ, 2006, ADV EXP MED BIOL, V586, P381
[8]   EPSTEIN-BARR-VIRUS COMPLEMENT C3D RECEPTOR IS AN INTERFERON-ALPHA RECEPTOR [J].
DELCAYRE, AX ;
SALAS, F ;
MATHUR, S ;
KOVATS, K ;
LOTZ, M ;
LERNHARDT, W .
EMBO JOURNAL, 1991, 10 (04) :919-926
[9]   COMPARING THE AREAS UNDER 2 OR MORE CORRELATED RECEIVER OPERATING CHARACTERISTIC CURVES - A NONPARAMETRIC APPROACH [J].
DELONG, ER ;
DELONG, DM ;
CLARKEPEARSON, DI .
BIOMETRICS, 1988, 44 (03) :837-845
[10]   Complement and its role in innate and adaptive immune responses [J].
Dunkelberger, Jason R. ;
Song, Wen-Chao .
CELL RESEARCH, 2010, 20 (01) :34-50